FI3737403T3 - Modifioituja adenoviruksia - Google Patents

Modifioituja adenoviruksia Download PDF

Info

Publication number
FI3737403T3
FI3737403T3 FIEP19711157.8T FI19711157T FI3737403T3 FI 3737403 T3 FI3737403 T3 FI 3737403T3 FI 19711157 T FI19711157 T FI 19711157T FI 3737403 T3 FI3737403 T3 FI 3737403T3
Authority
FI
Finland
Prior art keywords
cancer
mutation
adenovirus
binding
adenovirus according
Prior art date
Application number
FIEP19711157.8T
Other languages
English (en)
Finnish (fi)
Inventor
Alan Parker
Hanni Uusi-Kerttula
Original Assignee
Univ College Cardiff Consultants Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ College Cardiff Consultants Ltd filed Critical Univ College Cardiff Consultants Ltd
Application granted granted Critical
Publication of FI3737403T3 publication Critical patent/FI3737403T3/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10321—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10345—Special targeting system for viral vectors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FIEP19711157.8T 2018-02-16 2019-02-13 Modifioituja adenoviruksia FI3737403T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1802539.5A GB201802539D0 (en) 2018-02-16 2018-02-16 Modified adenoviruses
PCT/GB2019/050380 WO2019158914A1 (en) 2018-02-16 2019-02-13 Modified adenoviruses

Publications (1)

Publication Number Publication Date
FI3737403T3 true FI3737403T3 (fi) 2024-01-17

Family

ID=61783770

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP19711157.8T FI3737403T3 (fi) 2018-02-16 2019-02-13 Modifioituja adenoviruksia

Country Status (16)

Country Link
US (1) US12318418B2 (enExample)
EP (1) EP3737403B1 (enExample)
JP (3) JP7862138B2 (enExample)
KR (1) KR102687425B1 (enExample)
CN (2) CN118834841A (enExample)
AU (1) AU2019220607B2 (enExample)
CA (1) CA3090859C (enExample)
DK (1) DK3737403T5 (enExample)
ES (1) ES2968387T3 (enExample)
FI (1) FI3737403T3 (enExample)
GB (1) GB201802539D0 (enExample)
IL (1) IL276535B2 (enExample)
PL (1) PL3737403T3 (enExample)
PT (1) PT3737403T (enExample)
SG (1) SG11202007470QA (enExample)
WO (1) WO2019158914A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201507393TA (en) 2013-03-14 2015-10-29 Salk Inst For Biological Studi Oncolytic adenovirus compositions
ES2899913T3 (es) 2014-09-24 2022-03-15 Salk Inst For Biological Studi Virus tumorales oncolíticos y métodos de uso
EP3390645B1 (en) 2016-02-23 2022-09-14 Salk Institute for Biological Studies Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
WO2017147265A1 (en) 2016-02-23 2017-08-31 Salk Institute For Biological Studies High throughput assay for measuring adenovirus replication kinetics
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses
BR112020019942A2 (pt) 2018-04-09 2021-01-26 Salk Institute For Biological Studies composições de adenovírus oncolítico com propriedades de replicação aprimoradas
EP3812465A1 (en) * 2019-10-21 2021-04-28 Universität Ulm Adenovirus comprising a modified adenovirus hexon protein
WO2021205364A1 (en) * 2020-04-07 2021-10-14 Shenzhen Hua Yao Kang Ming Biopharmaceutical Co., Ltd. Engineered oncolytic adenovirus
CA3209730A1 (en) * 2021-03-29 2022-10-06 Alan Parker Modified adenovirus
GB202214580D0 (en) 2022-10-04 2022-11-16 Univ College Cardiff Consultants Ltd Adenoviral vector therapy
GB202314435D0 (en) 2023-09-20 2023-11-01 Univ College Cardiff Consultants Ltd Modified adenovirus
CN121203037B (zh) * 2025-09-26 2026-05-12 北京因诺惟康医药科技有限公司 基于整合素改造的特异性靶向心脏及肌肉的aav9优势突变体

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1516055A4 (en) 2002-01-24 2007-08-08 Scripps Research Inst FIBER OPERATING MODIFICATIONS FOR EFFICIENT TARGETS
CA2519680A1 (en) * 2003-03-28 2004-11-18 The Scripps Research Institute Adenovirus particles with enhanced infectivity of dendritic cells and particles with decreased infectivity of hepatocytes
GB0520068D0 (en) * 2005-10-03 2005-11-09 Cancer Res Technology av peptide ligand
ES2367227T3 (es) * 2007-03-14 2011-10-31 Institut Catala D'oncologia Adenovirus con mutaciones en el dominio de retención en el retículo endoplasmático de la proteína e3-19k y su utilización en el tratamiento del cáncer.
US20110104788A1 (en) * 2008-02-07 2011-05-05 Andrew Baker Modulation of Adenoviral Tropism
AU2011306846B2 (en) * 2010-09-24 2015-05-14 Oncos Therapeutics Oy Oncolytic adenoviral vectors and methods and uses related thereto
EP3247807B1 (en) 2015-01-20 2020-12-16 Adcure Biotechnologies, LLC. Detargeted adenovirus variants and related methods
GB201802539D0 (en) * 2018-02-16 2018-04-04 Univ College Cardiff Consultants Ltd Modified adenoviruses

Also Published As

Publication number Publication date
ES2968387T3 (es) 2024-05-09
CA3090859C (en) 2025-04-01
IL276535B1 (en) 2025-03-01
KR102687425B1 (ko) 2024-07-22
IL276535B2 (en) 2025-07-01
JP2024020345A (ja) 2024-02-14
JP2025081522A (ja) 2025-05-27
IL276535A (en) 2020-09-30
PL3737403T3 (pl) 2024-03-18
PT3737403T (pt) 2024-01-24
WO2019158914A1 (en) 2019-08-22
DK3737403T5 (da) 2024-08-26
JP2021513843A (ja) 2021-06-03
SG11202007470QA (en) 2020-09-29
CA3090859A1 (en) 2019-08-22
EP3737403A1 (en) 2020-11-18
JP7862138B2 (ja) 2026-05-19
CN112020368A (zh) 2020-12-01
AU2019220607A1 (en) 2020-09-17
CN118834841A (zh) 2024-10-25
EP3737403B1 (en) 2024-01-03
CN112020368B (zh) 2024-07-12
US20210100855A1 (en) 2021-04-08
KR20200122346A (ko) 2020-10-27
DK3737403T3 (da) 2024-01-22
US12318418B2 (en) 2025-06-03
AU2019220607B2 (en) 2024-02-15
GB201802539D0 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
JP2021513843A5 (enExample)
CN112020368B (zh) 修饰的腺病毒
JP2012513209A5 (enExample)
ES2871907T3 (es) Portadores de vacuna de adenovirus de chimpancé
FI3768830T3 (fi) Syöpäterapia
JP2020517635A5 (enExample)
KR20170018450A (ko) 세포 치료제로서의 car-발현 nk-92 세포
PT2293804E (pt) Vírus herpes simplex (hsv) com tropismo modificado, suas utilizações e processo de preparação
RU2011130511A (ru) Аденовирусные векторы и способы их применения, связанные с ними
JP2021530971A5 (enExample)
Chen et al. Aptamer modification improves the adenoviral transduction of malignant glioma cells
Verheije et al. Retargeting of viruses to generate oncolytic agents
JP2003531568A (ja) 組換え型アデノウイルス
WO2013135655A1 (en) Bi-specific adapters
Hallenbeck et al. Targetable gene delivery vectors
AU2022247189A1 (en) Modified adenovirus
Dmitriev et al. Targeted Adenoviral Vectors I: Transductional Targeting
Murray et al. Reduction of streptavidin RYDS-mediated renal adhesion by site-directed mutagenesis
HK40030481A (en) Modified adenoviruses
Yang et al. Cell‐penetrating peptide delivery of biologically active oct4 protein into cultured Takifugu rubripes spermary cells
Curiel Strategies to alter the tropism of adenoviral vectors via genetic capsid modification
HK40122461A (en) Method for producing an antitumoral arenavirus as well as arenavirus mutants
NZ782454A (en) Viral vector
RU2020131337A (ru) Модифицированные онколитические аденовирусы
Hausl et al. ADENOVIRUS VECTOR ENGINEERING